Note: Descriptions are shown in the official language in which they were submitted.
CA 02619473 2012-01-16
AN ASYMMETRIC SYNTHESIS OF (S)-(+)-3-(AMINOMETHYL)-5-METHYLHEXANOIC ACID
FIELD OF THE INVENTION .
[0002) The invention encompasses processes for the synthesis of (S)-(+)-3-
(aminomethyl)-5-methylhexanoic acid, (S)-Pregabalin, and intermediates of
(S)-Pregabalin.
BACKGROUND OF THE INVENTION
[0003) (S)-Pregabalin, (S)-(+)-3-(aminomethyl)-5-methylhexanoic acid, a
compound having the chemical structure,
H2N~ O
OH
is also known as Camino butyric acid or (S)-3-isobutyl GABA. (S)-Pregabalin,
marketed under the name LYRICA , has been found to activate GAD (L-glutamic
acid decarboxylase). (S)-Pregabalin has a dose dependent protective effect
on-seizure, and is a CNS-active compound. (S)-Pregabalin is useful in
anticonvulsant
therapy, due to its activation of GAD, promoting the production of GABA, one
of the
brain's major inhibitory neurotransmitters, which is released at 30 percent of
the
brains synapses. (S)-Pregabalin has analgesic, anticonvulsant, and anxiolytic
activity.
1
CA 02619473 2008-02-14
WO 2007/035890 PCT/US2006/036875
[0004] Several processes for the synthesis of (S)-Pregabalin are known. For
example, see DRUGS OF THE FUTURE, 24 (8), 862-870 (1999). One such process is
illustrated in scheme 1.
Scheme 1
0 OH 0 0 0 0 OH
AC20 1) NHH(aj. MTBE
HO `` 2) zci 0 (R}(}1~1-i mllm
0 CH3 CH3 f H2 CH3
H3 CI-3 CH3
2 3 4
0 0 H3N 0 OH. 0 OH.
0
xci 0 1) H101-1 33r2 I)HC1 2N
NHS .. CR NH2 yGFb CH3
CH3 CH3 CH3
(R)-6 Pregabalin
[0005] In Scheme 1, 3-isobutyl glutaric acid, compound 2, is converted into
the corresponding anhydride, compound 3, by treatment with refluxing acetic
anhydride. The reaction of the anhydride with NH4OH produces the glutaric acid
mono-amide, compound 4, which is resolved with (R)-1-phenylethylamine,
yielding
the (R)-phenylethylamine salt of (R)-3-(carbamoylmethyl)-5-methylhexanoic
acid,
compound 5. Combining the salt with an acid liberates the R enantiomer,
compound
6. Finally, a Hoffmann degradation with Br2/NaOH provides (S)-Pregabalin. A
disadvantage of this method is that it requires separating the two
enantiomers, thereby
resulting in the loss of half the product, such that the process cost is high.
[0006] Several stereoselective processes for the synthesis of (S)-Pregabalin
have been disclosed. For example, U.S. Patent No. 5,599,973 discloses the
preparation of (S)-Pregabalin using stoichiometric (+)-4-methyl-5-phenyl-2-
oxazolidinone as a chiral auxiliary that may be recycled. In general, however,
that
route is of limited use for scale-up, principally due to the low temperature
required for
the reactions, the use of pyrophoric reagent, such as, butyl lithium, to side
reactions,
and due to a low overall yield.
2
CA 02619473 2008-02-14
WO 2007/035890 PCT/US2006/036875
[0007] Another process is disclosed in U.S. Patent Application Publication
No. 2003/0212290, which discloses asymmetric hydrogenation of a cyano-
substituted
olefin, compound 7, to produce a cyano precursor of (S)-3-(aminomethyl)-5-
methyl
hexanoic acid, compound 8, as seen in scheme 2.
Scheme 2
CN CN
[(R,R)-McDuPHO S]Rh(COD)+BF4-
CO2R CO2R
7 8
[0008] Subsequent reduction of the nitrile in compound 8 by catalytic
hydrogenation produces (S)-Pregabalin. The cyan hexenoate starting material,
compound 7, is prepared from 2-methyl propanal and acrylonitrile (Yamamoto et
al,
Bull. Chen. Soc. Jap., 58, 3397 (1985)). However, the disclosed method
requires
carbon monoxide under high pressure, raising serious problems in adapting this
scheme for production scale processes.
[0009] A process published by G.M. Sammis, et al., J. Am. Chem. Soc.,
125(15), 4442-43 (2003), takes advantage of the asymmetric catalysis of
cyanide
conjugate addition reactions. The method discloses the application of aluminum
salen
catalysts to the conjugate addition of hydrogen cyanide to cx,f-unsaturated
imides as
shown in scheme 3. Reportedly, TMSCN is a useful source of cyanide that can be
used in the place of HCN. Although the reaction is highly selective, this
process is
not practicable for large scale production due to the use of highly poisonous
reagents.
Moreover, the last reductive step requires high pressure hydrogen, which only
adds to
the difficulties required for adapting this scheme for a production scale
process.
3
CA 02619473 2008-02-14
WO 2007/035890 PCT/US2006/036875
Scheme 3
0 J'/~ O O CN
N Ph~N
Ph H TMSCN, iPrOH, Cat H
9 10
0 CN 5% mot Pt02, HEN
NaOH, THE 3 500 psi H2
HO HO
11 Pregabalin
[0010] In 1989, Silverman reported a convenient synthesis of 3-alkyl-4-amino
acids compounds in SYNm1 sIs, Vol. 12, 953-944 (1989). Using 2-alkenoic esters
as
a substrate, a series of GABA analogs were produced by Michael addition of
nitromethane to a,(3-unsaturated compounds, followed by hydrogenation at
atmospheric pressure of the nitro compound to amine moiety as depicted in
scheme 4.
Scheme 4
OEt OEt 1OR
O O O
Y HZN
12 13 14
[0011] Further resolution of compound 14 may be employed to resolve
Pregabalin. This, of course, results in the loss of 50 percent of the product,
a serious
disadvantage. However, the disclosed methodology reveals that the nitro
compound
can serve as an intermediate for the synthesis of 3-alkyl-4-amino acids.
[0012] Recent studies have indicated that cinchona alkaloids are broadly
effective in chiral organic chemistry. A range of nitroalkenes were reportedly
treated
with dimethyl or diethyl malonate in THE in the presence of cinchona alkaloids
to
provide high enantiomeric selectivity of compound 15,
4
CA 02619473 2008-02-14
WO 2007/035890 PCT/US2006/036875
NO2
R1000COOR2
and its analogues. For example, see H. Li, et al., J. Ana. Chem. Soc.,
126(32), 9906-07
(2004). These catalysts are easily accessible from either quinine or
quinidine, and are
reportedly highly efficient for a synthetically C-C bond forming asymmetric
conjugate addition as shown in scheme 5.
Scheme 5
NO2
N02 R3 _
R3 \ CH2(CO2Me)2, THE
cat :cinchona alkaloid R100C COOR2
21
[0013] R3 represents several alkyl and aryl groups. The scope of the reaction
has been extended to other nitroolefins and applied to prepare ABT-546
employing
bis(oxazoline)Mg(OTf)2. See, for example, D.M. Barnes, et al., J. Am. Chem.
Soc.,
124(44), 13097-13105 (2002).
[0014] Other groups have investigated a new class of bifunctional catalysts
bearing a thiourea moiety and an amino group on a chiral scaffold. See T.
Okino, et
al., J Am.' Chem. Soc., 127(1), 119-125 (2005). On the basis of a catalytic
Michael
addition to the nitroolefin with enantiomeric selectivity, they were able to
prepare a
series of analogues of compound 15.
[0015] Thus, there is a need in the art for new processes for the preparation
of
(S)-Pregabalin that does not suffer from the disadvantages mentioned above.
SUMMARY OF THE INVENTION
[0016] In one embodiment, the invention encompasses (3S)-5-methyl-3- (2-
oxo-2{[(1S)-1-aryl-alkyl] amino) ethyl)hexanoic acid of the following formula
24,
5
CA 02619473 2008-02-14
WO 2007/035890 PCT/US2006/036875
R
Ar' NH OH
O O
24
wherein Ar is a C6-1o aromatic group, and R is a straight or branched C1_4
alkyl, ester
or carboxylic acid.
[0017] In another embodiment, the invention encompasses a (R)-3-
isobutylpentanedioic acid amide-((S)- 1 -aryl-alkyl)amide of the following
formula 25,
R
Ar~ `NH NHZ
O O
wherein Ar is a C6_10 aromatic group, and R is a straight or branched C1-4
alkyl, ester
or carboxylic acid.
[0018] In another embodiment, the invention encompasses a (S)-4-methyl-2-
{[((S)-1-aryl-alkyl-carbamoyl)-methyl]pentyl}carbamic acid methyl ester of the
following formula 26,
Arm R
NHCOOCH3
HN
O CH3
CH3
wherein Ar is a C6.1o aromatic group, and R is a straight or branched C1_4
alkyl, ester
or carboxylic acid.
[0019] In another embodiment, the invention encompasses a (S)-2-
carbamoylmethyl-4-methylpentyl)carbamic acid alkyl ester of the following
formula
27,
HZN
YrNHCOOR'
27
wherein R' is a straight or branched C1.5 alkyl.
6
CA 02619473 2008-02-14
WO 2007/035890 PCT/US2006/036875
[0020] In another embodiment, the invention encompasses a process for
preparing (S)-Pregabalin comprising: preparing a compound of the following
formula
24
R
Ar -"NH OH
r.': O
2wh
erein Ar is a C6_1o aromatic group and R is a straight or branched C1-4 alkyl,
ester,
or carboxylic acid; converting the compound of formula 24 into a compound of
the
following formula 25, wherein Ar is a C6_10 aromatic group, and R is a
straight or
branched C1_4 alkyl, ester, or carboxylic acid;
Ar ' NH NH2
O O
converting the compound of formula 25 into a compound of the following formula
26
ArR
NHCOOCH3
HN
O CH3
CH3
wherein Ar is a C6_10 aromatic group, and R is a straight or branched Cl-4
alkyl, ester,
or carboxylic acid; converting the compound of formula 26 into a compound of
the
following formula 27
HZN
;HCOOR'
0T27
7
CA 02619473 2008-02-14
WO 2007/035890 PCT/US2006/036875
wherein R' is a straight or branched C1.5 alkyl; and converting the compound
of
formula 27 into (S)-Pregabalin.
[0021] The compound of formula 24 is preferably prepared by a process
comprising: combining a chiral amine of the following formula 23,
z
Ar R
23
wherein Ar is a C6_10 aromatic group, and R is a straight or branched C1-4
alkyl, ester,
or carboxylic acid, an organic solvent selected from at least one of C6_10
aromatic
hydrocarbons, substituted aromatic hydrocarbons, C2.8 ethers, halogenated
hydrocarbons, straight or branched C1_4 alcohols, C3.8 esters, straight,
branched or
cyclic C1_6 alkanes, or C3_8 ketones, and at least one base, to obtain a
mixture; cooling
the mixture to a temperature of about -70 C to about 10 C; adding 3-isobutyl
glutaric
anhydride to the mixture; maintaining the mixture at a temperature of about -
70 C to
about 10 C for at least about one hour to obtain the compound of formula 24;
and
recovering the compound of formula 24 from the mixture.
[0022] The compound of formula 24 is preferably converted into the
compound of formula 25 by a process comprising: combining at a temperature of
about 20 C to about -30 C, the compound of formula 24 and at least one organic
solvent selected from the group consisting of substituted aromatic
hydrocarbons, C6_10
aliphatic hydrocarbons, halogenated carbons, ethers and ketones, an amidation
reagent
selected from the group consisting of C1_4 alkyl and C6_8 aryl haloformates,
and acid
halides, and a base to form a mixture; maintaining the mixture for about one
hour to
about two hours at a temperature of about -10 C to about 20 C; adding ammonia
to
obtain the compound of formula 25; and recovering the compound of formula 25
from
the mixture.
[0023] The compound of formula 25 is preferably converted into the
compound of formula 26 by a process comprising: combining a solution of the
compound of formula 25 in at least one straight or branched alkyl alcohol,
such as
methyl, ethyl, isopropyl, n-butyl, isobutyl, or t-butyl alcohol, preferably,
methanol or
ethanol, at a temperature of about -25 C to about -45 C with bromine, in the
presence
8
CA 02619473 2008-02-14
WO 2007/035890 PCT/US2006/036875
of at least one base, to obtain a basic mixture; warming the basic mixture to
a
temperature of about 50 C to about 70 C, preferably, about 55 C to about 60 C;
warming the basic mixture for about 1 hour to about 4 hours to obtain the
compound
of formula 26; and recovering the compound of formula 26 from the basic
mixture.
Preferably, the compound of formula 26 is obtained in a purity of about 90% to
about
100% area by HPLC, more preferably, in a purity of about 92% to about 100%
area
by HPLC, and, most preferably, in a purity of about 95% to about 100% area by
HPLC.
[0024] Preferably, the base is a metal alkoxide, such as sodium ethoxide,
sodium methoxide, potassium methoxide, potassium ethoxide, or potassium
tert-butoxide, and is preferably sodium ethoxide or sodium methoxide.
Preferably,
the compound of formula 26 is recovered by evaporating the solvent from the
basic
mixture to form a residue and extracting the compound of formula 26 from the
residue. Preferably, the compound of formula 26 is extracted with
dichloromethane,
ethyl acetate, or toluene: The recovered compound of formula 26 is preferably
crystallized from an organic solvent selected from at least one of ethers,
esters,
hydrocarbons, substituted hydrocarbons, and alcohols. Preferably, the organic
solvent
is diisopropyl ether, ethyl acetate, cyclohexane, dichloromethane, or
methanol.
[0025] Preferably, the compound of formula 26 is converted into the
compound of formula 27 by a process comprising: combining the compound of
formula 26 and a mixture of water and an ether to obtain a mixture; combining
the
mixture with ammonia and an alkali metal at a temperature of about -30 C to
about
-60 C, preferably, about -40 C to about -30 C, to obtain a reaction mixture;
maintaining the reaction mixture for about 4 to about 10 hours until the
excess of
ammonia is evaporated to obtain the compound of formula 27; and, preferably,
recovering the compound of formula 27 from the reaction mixture. Preferably,
the
ether is tetrahydrofuran or dioxane. Preferably, the ammonia is liquid
ammonia.
Preferably, the alkali metal is lithium or sodium. Preferably, the compound of
formula 27 is recovered by extraction, and, more preferably, the compound of
formula
27 is crystallized from an ether, such as diisopropyl ether.
[0026] Preferably, the compound of formula 27 is converted to (S)-Pregabalin
in a process comprising: combining the compound of formula 27 with an acid to
obtain a mixture; maintaining the mixture at a temperature of about 60 C to
about
9
CA 02619473 2011-07-26
130 C, preferably, about 80 C to about 1 IO C, for about 5 to about 30 hours,
preferably, for
about 18 to about 30 hours, and, more preferably, for about 5 to about 10
hours, to obtain (S)-
Pregabalin; and recovering the (S)-Pregabalin from the mixture. Preferably,
the acid is a strong
mineral acid, such as hydrochloric acid or sulfuric acid.
[0027] Preferably, the (S)-Pregabalin is recovered by a process comprising:
adjusting
the pH of the mixture to about 3 to about 1; extracting a solution of (S)-
Pregabalin from the
mixture with an alcohol; adjusting the pH of the solution to about 4 to about
7 to induce the
precipitation of (S)-Pregabalin; and recovering the precipitated (S)-
Pregabalin. Preferably, the
(S)-Pregabalin is obtained in a purity of at least about 98% area by HPLC,
and, more
preferably, about 99% to about 100% area by HPLC.
[0028] In another embodiment, the invention encompasses a process for
preparing (S)-
Pregabalin comprising: combining a compound of the following formula 26,
Ar----,R
NHCOOCH3
HN
O CH3
Y-ly
CH3
wherein Ar is a C6_io aromatic group, and R is a straight or branched C1
alkyl, ester, or
carboxylic acid, with an acid to obtain a mixture; maintaining the mixture at
a temperature of
about 60 C to about 130 C, for about 3 hours to about 30 hours, to obtain (S)-
Pregabalin; and
recovering the (S)-Pregabalin from the mixture.
[0029] In another embodiment, the invention encompasses a process for
recycling 3-
isobutyl glutaric anhydride comprising: preparing a compound of formula 24
from 3-isobutyl
glutaric anhydride by the process Of. combining a chiral amine of formula 23,
NH2
Ar,KR
23
wherein Ar is a C6-1o aromatic group, and R is a straight or branched C1
alkyl, ester, or
carboxylic acid, an organic solvent selected from at least one of C6.10
aromatic hydrocarbons,
substituted aromatic hydrocarbons, C2.g ethers, halogenated hydrocarbons,
straight or branched
C1 alcohols, C3_8 esters, straight, branched or cyclic C14alkanes, or C3_8
ketones, and at least
10a
CA 02619473 2011-07-26
one base, to obtain a mixture; cooling the mixture to a temperature of -70 C
to IO C; adding 3-
isobutyl glutaric anhydride to the mixture; maintaining the mixture at a
temperature of-70 C to
C for at least one hour to obtain a compound of formula 24; recovering the
compound of
formula 24 from the mixture and then crystallizing the recovered compound of
formula 24 from
an organic solvent; removing the crystals from the organic solvent; combining
the remaining
organic solvent with an acid to obtain a first mixture; maintaining the first
mixture at a
temperature of about 60 C to about 130 C, to obtain 3-isobutyl glutaric acid;
combining the 3-
isobutyl glutaric acid with acetic anhydride to obtain a second
l0b
CA 02619473 2008-02-14
WO 2007/035890 PCT/US2006/036875
mixture; heating the second mixture to a temperature of about 125 C to about
145 C
to obtain 3-isobutyl glutaric anhydride; and recovering the 3-isobutyl
glutaric
anhydride from the second mixture.
[0030] In another embodiment, the invention encompasses (S)-pregabalin
having an enantiomeric purity of about 99% to about 100% area by HPLC,
preferably
of about 99.9% to about 100% area by HPLC.
BRIEF DESCRIPTION OF THE FIGURES
[0031] Figure 1 illustrates an IR spectrum of (3S)-5-methyl-3- (2-oxo-
2 {[(1 S)-1-phenylmethyl] amino) ethyl)hexanoic acid of formula 24A.
[0032] Figure 2 illustrates a 1H-NMR spectrum of (3S)-5-methyl-3- (2-oxo-
2{[(1S)-1-phenylmethyl]amino }ethyl)hexanoic acid of formula 24A.
[0033] Figure 3 illustrates a 13C-NMR spectrum of (3S)-5-methyl-3- (2-oxo-
2{[(1S)-1-phenylmethyl]amino} ethyl)hexanoic acid of formula 24A.
[0034] Figure 4 illustrates a powder X-ray diffraction pattern of (3S)-5-
methyl-3- (2-oxo-2{[(1S)-1-phenylmethyl]amino}ethyl)hexanoic acid of formula
24A.
DETAILED DESCRIPTION OF THE INVENTION
[0035] The present invention provides a stereos elective synthesis of (S)-
Pregabalin according to the following scheme:
Scheme 6
R
R
Ar' NH OH
Ar1'NH NH2
0
0 0
24
26
R HZN\
Q
Ar.'JINH H N NHCOOR' Ih
NHCOOR' QH
26 27
(S)-Pregabalin
11
CA 02619473 2008-02-14
WO 2007/035890 PCT/US2006/036875
This process allows for obtaining (S)-Pregabalin with a relatively high
enantiomeric
purity.
[0036] The invention encompasses (3S)-5-methyl-3-(2-oxo-2{[(1 S)-l-aryl-
alkyl] amino} ethyl)hexanoic acids of formula 24,
R
Ar NH OH
r.': O
2wh
erein Ar is a C6_10 aromatic group and R is a straight or branched C1_4 alkyl,
ester,
or carboxylic acid.
[0037] Preferably, the C6_10 aromatic group is naphthyl, phenyl, substituted
phenyl, or substituted naphthyl, more preferably phenyl. Preferably, the
substituted
phenyl is a phenyl group substituted with at least one of alkoxy, halogen,
alkyl,
carboxylic acid, or ester. A preferred alkoxy phenyl is methoxyphenyl.
Preferred
halogenated phenyls are chlorobenzene, bromobenzene, and fluorobenzene.
Preferred
alkylated phenyls are either toluene or ethylbenzene. Preferably, the
carboxylic acid
substituent is -COOH, -CH2COOH, -CH(CH3)COOH or -C(CH3)2COOH. Preferably
the ester substituent is a methylester, ethylester, isopropylester, n-
butylester, isobutyl,
or t-butyl derivative of one of the above-listed carboxylic acid substituents.
[0038] Preferably, the C1-4 alkyl is methyl, ethyl, isopropyl, n-butyl,
isobutyl
or t-butyl, more preferably, methyl.
[0039] When Ar is phenyl and R is methyl, the compound of formula 24 is
(3S)-5-methyl-3-(2-oxo-2 {[(1 S)-1-phenylmethyl]amino) ethyl)hexanoic acid 24A
Me
Ph NH OH
I I
r.. O
2whi
ch may be characterized by data selected from: a 13C- NMR (CDC13, 300 MHz)
spectrum having carbon chemical shifts at about 21.74, 22.19, 22.66, 24.95,
29.44,
30.89, 36.73, 38.15, 40.55, 43.45, 48.92, 125.41, 126.06, 127.29, 128.57,
143.01,
12
CA 02619473 2008-02-14
WO 2007/035890 PCT/US2006/036875
171.92 and 176.71 ppm; a 1H-NMR (CDC13, 75 MHz) spectrum having hydrogen
chemical shifts at about 0.77, 1.18, 1.38, 1.56, 2.22, 5.03, 6.59-6.62, 7.11-
7.22 and
10.88 ppm; and an JR spectrum having peaks at about 3321.39, 2955.91, 1693.33,
1617.43, 1561.07 and 698.24 cm 1.
[0040] The invention also encompasses isolated (3S)-5-methyl-3-(2-oxo-
2{[(1S)-1-phenylmethyl]amino} ethyl)hexanoic acid 24A, preferably in
crystalline
form. The crystalline form of 24A may be characterized by a powder X-ray
diffraction pattern having peaks at about 4.3 , 6.9 , 7.2 , and 7.7 20 0.2
20. The
crystalline form of 24A may be further characterized by X-ray powder
diffraction
peaks at about 6.3 , 8.1 , 9.7 , 10.3 , 11.3 , 12.9 , 13.9 , 15.1 , 15.7 ,
17.5 , 18.6 ,
19.1 , 20.5 , 20.9 , 21.8 , 22.3 , 23.3 , and 23.8 20 0.2 20. Moreover,
the
crystalline form of 24A may have a melting range of about 95 C to about 98 C.
[0041] The invention also encompasses isolated (3S)-5-methyl-3-(2-oxo-
2{[(1S)-1-phenylmethyl]amino) ethyl)hexanoic acid 24A having an optical purity
of
at least about 80% area by HPLC, preferably of at least about 93% area by
HPLC,
more preferably, of about 98% to about 100% area by HPLC, most preferably, of
about 99% to about 100% area by HPLC.
[0042] The invention also encompasses (R)-3-isobutylpentanedioic acid
R
Ar~ ., NH NH2
O O
amide-((S)-1-aryl-alkyl)amides of formula 25,
wherein Ar is a C64o aromatic group, and R is a straight or branched C1_4
alkyl, ester,
or carboxylic acid.
[0043] Where Ar is phenyl and R is methyl, the compound of formula 25 is
(R)-3-isobutylpentanedioic acid amide-((S)-1-phenylmethyl)amide 25A.
Me
Ph) ., NH NH2
O O
25A
13
CA 02619473 2008-02-14
WO 2007/035890 PCT/US2006/036875
[0044] The invention further encompasses (S)-4-methyl-2-{[((S)-1-aryl-alkyl-
carbamoyl)-methyl]pentyl}carbamic acid methyl esters of formula 26,
ArR
NHCOOCH3
HN
O CH3
CH3
wherein Ar and R are as defined above for formula 24.
[0045] When Ar is phenyl and R and is methyl, the compound of formula 26
is (S)-4-methyl-2-[((S)-1-aryl-alkyl-carbamoyl)-methyl]pentyl}carbamic acid
methyl
ester 26A.
Me
Ph NH
7NHCOOCH3
26A
[0046] The invention also encompasses (S)-2-carbamoylmethyl-4-
methylpentyl)carbamic acid alkyl esters of formula 27,
HEN
NHCOOR'
O
27
wherein R' is a straight or branched C1_5 alkyl, preferably, methyl.
[0047] When R' is methyl, the compound of formula 27 is (S)-2-
carbamoylmethyl-4-methylpentyl)carbamic acid methyl ester 27A.
HEN
NHCOOMe
0
27A
14
CA 02619473 2008-02-14
WO 2007/035890 PCT/US2006/036875
[0048] Further, the invention encompasses a process for the preparation of
(S)-Pregabalin via the intermediate compound of formula 24. The process
comprises
preparing the intermediate of formula 24, converting the intermediate compound
of
formula 24 into the diamide of formula 25, converting the diamide of formula
25 into
the chiral carbamate of formula 26, converting the chiral carbamate into the
compound of formula 27, and converting the compound of formula 27 into
(S)-Pregabalin. Although each of the compounds of formula 24, formula 25,
formula
26, and formula 27 can be isolated prior to conversion, isolation of the
compounds of
formula 26 and formula 27 is not required. Therefore, once the compound of
formula
25 has been prepared and isolated, the preparation of the compound of formula
27
from the compound of formula 25 or the compound of formula 26 and the
preparation
of (S)-Pregabalin from the compound of formula 25 or the compound of formula
26
does not require isolation of any of the intermediate compounds. Thus, once
the
compound of formula 25 has been prepared and isolated, (S)-Pregabalin can be
prepared in a one-pot process without the isolation of either of the compounds
of
formula 26 or formula 27.
[0049] The intermediate compound of formula 24 may be prepared by
combining a chiral amine of formula 23,
2
Ar R
23
an organic solvent selected from at least one of C6_10 aromatic hydrocarbons,
substituted aromatic hydrocarbons, C2-8 ethers, halogenated hydrocarbons,
straight or
branched Cl-4 alcohols, C3_8 esters, straight, branched or cyclic C1_6
alkanes, or C3_8
ketones, and at least one base, to obtain a mixture, cooling the mixture, and
adding 3-
isobutyl glutaric anhydride of formula 22
0 0 0
22
to the mixture to obtain the compound of formula 24,
CA 02619473 2012-01-16
R
"NH OH
O O
2A
which is then recovered.
[0050] The 3-isobutyl glutaric anhydride of formula 22 may be prepared
according to the
process disclosed in US. Patent No. 5,616,793.
[0051) The chiral amine of formula 23 is commercially available, and is used
as a chiral
auxiliary is a primary amine or a chiral amino acid derivative, wherein Ar and
R are as defined
above for the compound of formula 24. Preferably, the chiral amine of formula
23 is
methylbenzylamine, and more preferably the chiral amine of formula 23 is (S)-
methylbenzylamine.
[0052] Preferably, the aromatic hydrocarbon is toluene. The preferred ether is
selected
from tort-butyl methyl ether, tetrahydrofuran, diisopropyl ether, and diethyl
ether. Preferably, the
halogenated hydrocarbon is dichloromethanc. Preferred C14 alcohols are
isopropyl alcohol,
ethanol, methanol, or n-butanol. Preferably, the ester is selected from ethyl
acetate, isopropyl
acetate, and isobutyl acetate. A preferred straight, branched or cyclic CI-6
alkane is either hexane
or cyclohcxanc. Preferred ketones are selected from acetone, methyl isobutyl
ketone, and methyl
ethyl ketone. The more preferred organic solvent is toluene.
[0053] Preferably, the base is an organic base selected from diethyl amine,
triethyl
amine, di-n-propyl amine, di-isopropyl amine, tertbutylamine, morpholine,
piperidine, pyridine,
and 4-dimethyl aminopyridine. The most preferred base is 4-dimethyl
aminopyridine.
[0054] Preferably, the mixture is cooled to a temperature of about -70 C to
about 10 C
before adding the 3-isobutyl glutaric anhydride.
[0055] Preferably, the mixture is maintained at a temperature of about -70 C
to about
C, more preferably of about 0 C to about -50 C and most preferably of about -
40 C to -30 C,
before recovering the compound of formula 24. Preferably, the mixture is
maintained for at least
about one hour, more preferably about one hour to about six hours, most
preferably, about one
hour to about two hours, before recovering the compound of formula 24.
16
CA 02619473 2008-02-14
WO 2007/035890 PCT/US2006/036875
[0056] The order of combining the reacting substances when preparing the
compound of formula 24 may influence the purity and the yield of the final
product.
Preferably, the chiral amine of formula 23 is combined with the base, followed
by the
addition of the 3-isobutylglutaric anhydride of formula 22.
[0057] The compound of formula 24 may be recovered by any method known
in the art, such as extracting the organic phase with an aqueous basic
solution to
convert the acidic product to a salt, and acidifying the aqueous phase with a
mineral
acid to obtain back the acid product.
[0058] The compound of formula 24 may optionally be further purified by a
crystallization from an organic solvent selected from at least one of esters,
nitriles,
ethers, C4_6 straight, branched, or cyclic hydrocarbons, and C6_10 substituted
aromatic
hydrocarbons. A preferred ester is ethyl acetate. Preferably, the nitrile is
acetonitrile.
A preferred ether is methyl t-butyl ether. A preferred C6_8 substituted
aromatic group
is either toluene or xylene. Preferred mixtures are that of xylene and ethyl
acetate,
hexane and ethyl acetate, cyclohexane and ethyl acetate, and toluene and ethyl
acetate. The most preferred mixture is that of toluene and ethyl acetate.
[0059] The compound of formula 24 obtained by the above-described process
has an optical purity of at least about 80% area by HPLC, preferably of at
least about
93% area by HPLC, more preferably of about 98% to about 100% area by HPLC, and
most preferably of about 99% to about 100% area by HPLC.
[0060] The recovered compound of formula 24 is then converted to the
diamide of formula 25,
R
I
Ar/ NH
NH2
O O
Y I
in aprocess comprising combining a mixture of the compound of formula 24 and
at
least one organic solvent selected from substituted aromatic hydrocarbons,
C6.10
aliphatic hydrocarbons, halogenated carbons, ethers and ketones, an amidation
reagent
selected from C1_4 alkyl and C6_8 aryl haloformates, and acid halides, and at
least one
base, and adding ammonia to obtain the compound of formula 25, which is then
recovered.
17
CA 02619473 2008-02-14
WO 2007/035890 PCT/US2006/036875
[0061] Preferably, the ammonia is provided in an aqueous solution, i.e.,
ammonium hydroxide.
[0062] Preferably, the C1_4 alkyl halo formate is a ethyl or methyl derivative
of
a chloro or bromoformate. Preferably, the C6_8 aryl halo formate is a benzyl
chloro or
bromoformate. Preferred acid halides are acetyl, pivaloyl, oxaloyl or benzoyl
chlorides and bromides. The most preferred haloformate is either
ethylchloroformate
or methylchloroformate. The more preferred acid halide is acetyl, pivaloyl,
oxaloyl,
or benzoyl chlorides. The most preferred amidation reagent is either
ethylchloroformate or methylchloroformate.
[0063] Preferably, the substituted aromatic hydrocarbon is either toluene or
xylene. A preferred C6_10 aliphatic hydrocarbon is either hexane or heptane.
Preferred ketones are acetone, methyl ethyl ketone, or methyl isobutyl ketone.
Preferably, the ether is diethyl ether, diisopropyl ether, or tert-butyl
methyl ether.
Preferably, the halogenated hydrocarbon is dichloromethane. The more preferred
organic solvent is either acetone or dichloromethane.
[0064] Preferably, the base is an organic base selected from diethyl amine,
triethyl amine, di-n-propyl amine, di-isopropyl amine, tri-n-butyl amine,
morpholine,
piperidine, pyridine, and 4-dimethyl aminopyridine. The preferred base is
either
4-dimethyl aminopyridine or triethyl amine.
[0065] Preferably, the mixture of the compound of formula 24 and an organic
solvent is combined with the amidation reagent and the base at a temperature
of about
20 C to about -30 C, more preferably, of about -10 C to about -20 C.
Preferably, the
compound of formula 24 is compound 24A.
[0066] Preferably, the mixture is maintained at a temperature of about -10 C
to about -20 C before the addition of ammonia. Preferably, the mixture is
maintained
for about one hour to about two hours before the addition of ammonia.
[0067] The compound of formula 25 may be recovered by known methods in
the art, such as, filtering and drying.
[0068] The compound of formula 25 is obtained by the above process having
a purity of at least about 80% area by HPLC, more preferably of at least about
95%
area by HPLC.
[0069] Then, the recovered compound of formula 25 is reacted with bromine
in a Hoffinan reaction under basic conditions. The process comprises combining
a
18
CA 02619473 2008-02-14
WO 2007/035890 PCT/US2006/036875
solution of a compound of formula 25 in at least one straight or branched
alkyl
alcohol with bromine, in a presence of at least one base, to obtain a basic
mixture, and
warming the basic mixture to obtain the chiral carbamate of formula 26,
ArR
NHCOOCH3
HN
0 Ly0H3
CH3
which is then recovered.
[0070] Preferably the combining step is performed at a temperature of about
-25 C to about -45 C. '"
[0071] Preferably, the base is a metal alkoxide selected from sodium ethoxide,
sodium methoxide, potassium methoxide, potassium ethoxide, and potassium
tert-butoxide. The more preferred base is either sodium ethoxide or sodium
methoxide.
[0072] Preferably, the basic mixture is warmed to a temperature of about 50 C
to about 70 C, more preferably to a temperature of about 55 C to about 60 C.
[0073] Preferably, the straight or branched alkyl alcohol is methyl, ethyl,
isopropyl, n-butyl, isobutyl, or t-butyl alcohol, more preferably methanol or
ethanol.
[0074] Preferably, the basic mixture is warmed for about 1 hour to about 4
hours before recovering the compound of formula 26.
[0075] The compound of formula 26 may be recovered by evaporating the
solvent and further extracting with a solvent selected from dichloromethane,
ethylacetate and toluene, followed by drying over a drying agent, such as,
magnesium
sulfate, followed by evaporating the solvent.
[0076] The recovered compound of formula 26 may be purified by
crystallization from at least one of an ether, ester, hydrocarbone,
substituted
hydrocarbon, or alcohol. Preferably, the compound of formula 26 is
crystallized from
at least one of diisopropyl ether, ethyl acetate, cyclohexane,
dichloromethane, or
methanol.
[0077] The compound of formula 26 is obtained by the above process having
a purity of at least about 80% area by HPLC, preferably of about 90% to about
100%,
19
CA 02619473 2008-02-14
WO 2007/035890 PCT/US2006/036875
area by HPLC, more preferably of about 92% to about 100% area by HPLC, and
most
preferably, of about 95% to about 100% area by HPLC.
[0078] The amide moiety of the recovered compound of formula 26 is then
converted to a primary amide moiety, to give the compound of formula 27
HZN
NHCOOR'
O
27
in a process comprising combining the compound of formula 26 and a mixture of
water and an ether to obtain a mixture, combining the mixture with ammonia and
an
alkali metal to obtain a reaction mixture, and evaporating the excess of
ammonia to
obtain the compound of formula 27.
[0079] Preferably, the mixture containing the compound of formula 26 and a
mixture of water and ether is combined with ammonia and an alkali metal at a
temperature of about -30 C to about -60 C, more preferably at a temperature of
about
-40 C to about-30 C.
[0080] Preferably the ether is either tetrahydrofuran or dioxane.
[0081] Preferably the ammonia is liquid.
[0082] The preferred alkali metal is either lithium or sodium.
.[0083]- Preferably, the excess ammonia is evaporated by maintaining the
reaction mixture for about 4 to about 10 hours.
[0084] The compound of formula 27 maybe recovered by any known method
in the art, such as, extraction and drying over anhydrous sodium sulfate.
[0085] _ The compound of formula 27 may optionally be purified by
crystallization from ether, preferably, diisopropyl ether.
[0086] The compound of formula 27 is then converted to (S)-Pregabalin in a
process comprising combining the compound of formula 27" with an acid to
obtain a
mixture and recovering (S)-Pregablin from the mixture.
[0087] Preferably, the acid is a strong mineral acid, more preferably either
hydrochloric acid or sulfuric acid.
[0088] Preferably, the mixture is maintained at a temperature of about 60 C to
about 130 C, more preferably of about 80 C to about 110 C, before recovering
the
(S)-Pregabalin.
CA 02619473 2008-02-14
WO 2007/035890 PCT/US2006/036875
[0089] Preferably, the mixture is maintained for about 5 to about 30 hours
before recovering the (S)-Pregabalin.
[0090] Preferably, the mixture is maintained for about 18 to about 30 hours,
when the mineral acid is hydrochloric acid and for about 5 to about 10 hours,
when
the mineral acid is sulfuric acid, before recovering the (S)-Pregabalin.
[0091] (S)-Pregabalin maybe recovered by adjusting the pH of the mixture to
about 3 to about 1, preferably by addition of a strong base; extracting a
solution of
(S)-Pregabalin from the mixture with an alcohol; adjusting the pH of the
solution to
about 4 to about 7, preferably with an inorganic or an organic base, to induce
the
precipitation of (S)-Pregabalin; and recovering the precipitated (S)-
Pregabalin.
[0092] (S)-Pregabalin obtained by the above process has at least about 80%
enantiomeric purity by area HPLC, preferably at least about 93% area by HPLC,
more
preferably, about 98% to about 100% area by HPLC, even more preferably, about
99% to about 100% area by HPLC, and most preferably of about 99.9% to about
100% area by HPLC.
[0093] In an alternative process, the chiral carbamate compound of formula 26
may be converted directly to (S)-Pregabalin. The process comprises combining
the
compound of formula 26 with an acid to obtain a mixture and maintaining the
obtained mixture at a temperature of about 60 C to about 130 C, for about 3
hours to
about 30 hours, to obtain (S)-Pregabalin, which is then recovered.
[0094] . Preferably, the acid is a strong mineral acid. Preferably, the strong
mineral acid is selected from a group consisting of hydrochloric acid,
hydrobromic
acid, and sulfuric acid.
[0095] Preferably, the mixture is maintained at temperature of about 80 C to
about 125 C.
[0096] Preferably, the mixture is maintained for about 10 to about 30 hours
when the mineral acid is hydrochloric acid, for about 5 to about 10 hours when
the
mineral acid is sulfuric acid, and for about 3 hours when the mineral acid is
hydrobromic acid.
[0097] (S)-Pregabalin may be recovered by the same method described for the
reaction of converting the compound of formula 27 to (S)-Pregabalin.
[0098] Further, 3-isobutyl glutaric anhydride of formula 22 can be regenerated
by a process comprising the steps of combining the filtrate obtained from the
21
CA 02619473 2008-02-14
WO 2007/035890 PCT/US2006/036875
crystallization process of compound of formula 24A with an acid to form a
first
mixture, recovering 3-isobutyl glutaric acid of the following formula 28
HO
OH
O O
Y' I
28
from the first mixture, combining the 3-isobutyl glutaric acid with acetic
anhydride to
obtain a second mixture, and recovering 3-isobutyl glutaric anhydride of
formula 22
from the second mixture, which may then be reused.
[0099] Preferably, the acid is a strong mineral acid, more preferably either a
4N to 12N hydrochloric acid or 20 percent to 80 percent sulfuric acid.
[00100] Preferably the first mixture is maintained at a temperature of about
60 C to about 130 C before recovering the 3-isobutyl glutaric acid.
Preferably, when
the mineral acid is hydrochloric acid, the first mixture is maintained at
temperature of
about 100 C to about 110 C before recovering the 3-isobutyl glutaric acid.
Preferably, when the mineral acid is sulfuric acid, the first mixture is
maintained at a
temperature of about 60 C to about 130 C before recovering the 3-isobutyl
glutaric
acid.
[00101] Preferably, the second mixture is heated to a temperature of about
125 C to about 145 C, more preferably, of about 130 C to about 140 C, before
recovering the 3-isobutyl glutaric anhydride.
[00102] The 3-isobutyl glutaric anhydride may be recovered by any method
known in the art, such as, distilling the excess of acetic anhydride and
cooling.
[00103] In yet another embodiment, the present invention provides
pharmaceutical compositions comprising enantiomerically pure (S)-Pregabalin
and at
least one pharmaceutically acceptable excipient. Such (S)-Pregabalin has at
least
about 80% enantiomeric purity, preferably of at least about 93% area by HPLC,
more
preferably, of about 98% to about 100% area by HPLC, even more preferably, of
about 99% to about 100% area by HPLC, and most preferably of about 99.9% to
about 100% area by HPLC. Such pharmaceutical composition can be prepared by
combining (S)-Pregabalin with one or more excipients or adjuvants. Selection
of
excipients and the amounts to use may be readily determined by the formulation
22
CA 02619473 2008-02-14
WO 2007/035890 PCT/US2006/036875
scientist based upon experience and consideration of standard procedures and
reference works in the field.
[00104] Diluents increase the bulk of a solid pharmaceutical composition, and
may make a pharmaceutical dosage form containing the composition easier for
the
patient and care giver to handle. Diluents for solid compositions include, for
example, microcrystalline cellulose (e.g. Avicel ), microfine cellulose,
lactose, starch,
pregelitinized starch, calcium carbonate, calcium sulfate, sugar, dextrates,
dextrin,
dextrose, dibasic calcium phosphate dihydrate, tribasic calcium phosphate,
kaolin,
magnesium carbonate, magnesium oxide, maltodextrin, mannitol,
polymethacrylates
(e.g. Eudragit ), potassium chloride, powdered cellulose, sodium chloride,
sorbitol,
and talc.
[00105] Solid pharmaceutical compositions that are compacted into a dosage
form, such as a tablet, may include excipients whose functions include helping
to bind
the active ingredient and other excipients together after compression. Binders
for
solid pharmaceutical compositions include acacia, alginic acid, carbomer (e.g.
carbopol), carboxymethylcellulose sodium, dextrin, ethyl cellulose, gelatin,
guar gum,
hydrogenated vegetable oil, hydroxyethyl cellulose, hydroxypropyl cellulose
(e.g.
Klucel ), hydroxypropyl methyl cellulose (e.g. Methocel ), liquid glucose,
magnesium aluminum silicate, maltodextrin, methylcellulose, polymethacrylates,
povidone (e.g. Kollidon , Plasdone ), pregelatinized starch, sodium alginate,
and
starch.
[00106] The dissolution rate of a compacted solid pharmaceutical composition
in the patient's stomach may be increased by the addition of a disintegrant to
the
composition. Disintegrants include alginic acid, carboxymethylcellulose
calcium,
carboxymethylcellulose sodium (e.g. Ac-Di-Sol , Primellose ), colloidal
silicon
dioxide, croscarmellose sodium, crospovidone (e.g. Kollidon , Polyplasdone ),
guar
gum, magnesium aluminum silicate, methyl cellulose, microcrystalline
cellulose,
polacrilin potassium, powdered cellulose, pregelatinized starch, sodium
alginate,
sodium starch glycolate (e.g. Explotab ), and starch.
[00107] Glidants can be added to improve the flowability of a non-compacted
solid composition and to improve the accuracy of dosing. Excipients that may
function as glidants include colloidal silicon dioxide, magnesium trisilicate,
powdered
cellulose, starch, talc, and tribasic calcium phosphate.
23
CA 02619473 2008-02-14
WO 2007/035890 PCT/US2006/036875
[00108] When a dosage form such as a tablet is made by the compaction of a
powdered composition, the composition is subjected to pressure from a punch
and die.
Some excipients and active ingredients have a tendency to adhere to the
surfaces of
the punch and die, which can cause the product to have pitting and other
surface
irregularities. A lubricant can be added to the composition to reduce adhesion
and
ease the release of the product from the die. Lubricants include magnesium
stearate,
calcium stearate, glyceryl monostearate, glyceryl palmitostearate,
hydrogenated castor
oil, hydrogenated vegetable oil, mineral oil, polyethylene glycol, sodium
benzoate,
sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc, and zinc
stearate.
[00109] Flavoring agents and flavor enhancers make the dosage form more
palatable to the patient. Common flavoring agents and flavor enhancers for
pharmaceutical products that may be included in the composition of the present
invention include maltol, vanillin, ethyl vanillin, menthol, citric. acid,
fumaric acid,
ethyl maltol, and tartaric acid.
[00110] Solid and liquid compositions may also be died using any
pharmaceutically acceptable colorant to improve their appearance and/or
facilitate
patient identification of the product and unit dosage level.
[00111] In liquid pharmaceutical compositions of the present invention, the
active ingredient and any other solid excipients are suspended in a liquid
carrier such
as water, vegetable oil, alcohol, polyethylene glycol, propylene glycol or
glycerin.
[00112] Liquid pharmaceutical compositions may contain emulsifying agents
to disperse uniformly throughout the composition an active ingredient or other
excipient that is not soluble in the liquid carrier. Emulsifying agents that
may be
useful in liquid compositions of the present invention include, for example,
gelatin,
egg yolk, casein, cholesterol, acacia, tragacanth, chondrus, pectin, methyl
cellulose,
carbomer, cetostearyl alcohol, and cetyl alcohol.
[00113] Liquid pharmaceutical compositions of the present invention may also
contain a viscosity enhancing agent to improve the mouth-feel of the product
and/or
coat the lining of the gastrointestinal tract. Such agents include acacia,
alginic acid
bentonite, carbomer, carboxymethylcellulose calcium or sodium, cetostearyl
alcohol,
methyl cellulose, ethylcellulose, gelatin guar gum, hydroxyethyl cellulose,
hydroxypropyl cellulose, hydroxypropyl methyl cellulose, maltodextrin,
polyvinyl
24
CA 02619473 2008-02-14
WO 2007/035890 PCT/US2006/036875
alcohol, povidone, propylene carbonate, propylene glycol alginate, sodium
alginate,
sodium starch glycolate, starch tragacanth, and xanthan gum.
[00114] Sweetening agents such as sorbitol, saccharin, sodium saccharin,
sucrose, aspartame, fructose, mannitol, and invert sugar may be added to
improve the
taste.
[00115] Preservatives and chelating agents such as alcohol, sodium benzoate,
butylated hydroxy toluene, butylated hydroxyanisole, and ethylenediamine
tetraacetic
acid may be added at levels safe for ingestion to improve storage stability.
[00116] According to the present invention, a liquid composition may also
contain a buffer such as gluconic acid, lactic acid, citric acid or acetic
acid, sodium
gluconate, sodium lactate, sodium citrate, or sodium acetate.
[00117] Selection of excipients and the amounts used may be readily
determined by the formulation scientist based upon experience and
consideration of
standard procedures and reference works. in the field.
[00118] The solid compositions of the present invention include powders,
granulates, aggregates, and compacted compositions. The dosages include
dosages
suitable for oral, buccal, rectal, parenteral (including subcutaneous,
intramuscular, and
intravenous), inhalant, and ophthalmic administration. Although the most
suitable
administration in any given case will depend on the nature and severity of the
condition being treated, the most preferred route of the present invention is
oral. The
dosages may be conveniently presented in unit dosage form and prepared by any
of
the methods well known in the pharmaceutical arts.
[00119] Dosage forms include solid dosage forms like tablets, powders,
capsules, suppositories, sachets, troches, and losenges, as well as liquid
syrups,
suspensions, and elixirs.
[00120] The dosage form of the present invention maybe a capsule containing
the composition, preferably a powdered or granulated solid composition of the
invention, within either a hard or soft shell. The shell may be made from
gelatin, and,
optionally, contain a plasticizer such as glycerin and sorbitol, and an
opacifying agent
or colorant.
[00121] The active ingredient and excipients may be formulated into
compositions and dosage forms according to methods known in the art.
CA 02619473 2008-02-14
WO 2007/035890 PCT/US2006/036875
[00122] A composition for tableting or capsule filling can be prepared by wet
granulation. In wet granulation, some or all of the active ingredients and
excipients in
powder form are blended, and then further mixed in the presence of a liquid,
typically
water, that causes the powders to clump into granules. The granulate is
screened
and/or milled, dried, and then screened and/or milled to the desired particle
size. The
granulate may then be tableted or other excipients may be added prior to
tableting,
such as a glidant and/or a lubricant.
[00123] A tableting composition can be prepared conventionally by dry
blending. For example, the blended composition of the actives and excipients
may be
compacted into a slug or a sheet, and then comminuted into compacted granules.
The
compacted granules may subsequently be compressed into a tablet.
[00124] As an alternative to dry granulation, a blended composition may be
compressed directly into a compacted dosage form using direct compression
techniques. Direct compression produces a more uniform tablet without
granules.
Excipients that are particularly well suited for direct compression tableting
include
microcrystalline cellulose, spray dried lactose, dicalcium phosphate dihydrate
and
colloidal silica. The proper use of these and other excipients in direct
compression
tableting is known to those in the art with experience and skill in particular
formulation challenges of direct compression tableting.
[00125] A capsule filling of the present invention may comprise any of the
aforementioned blends and granulates that were described with reference to
tableting,
however, they are not subjected to a final tableting step.
[00126] In another embodiment, the present invention provides a method of
treating a patient comprising administering to a patient in need thereof a
therapeutically effective amount of the above crystalline form of 0-
desmethylvenlafaxine. Preferably, the patient suffers from a condition which
may be
treated with a norepinephrine or a serotonin re-uptake inhibitor. Such patient
may be
suffering from depression.
[00127] The following non-limiting examples are merely illustrative of the
preferred embodiments of the present invention, and are not to be construed as
limiting the invention, the scope of which is defined by the appended claims.
26
CA 02619473 2012-01-16
EXAMPLES
Chiral HPLC analysis
Instrument: Waters-2487
Column: CHIRALPACK4;AD-H, 250x4.6 mm, Sum
Mobile phase: 2% TFA in n-Hexane/Ethanol - 95/5
Flow: 0.5 ml/minuto
Temperature: 30 C
Wavelength: 210 nmIUV visible spectrophotometer
EI-NMR analysis
F2-Acquisition parameters F2-Processing parameters
Instrument dpx 300
Probhd 5 mm Dual Z5 SI 32768
Puiprog zg SF 300.13000292MHz
TD 16384 WDW EM
Solvent CDC13 SSB 0
NS 8 LB 0.50 Hz
DS 0 GB 0
SWH 3992.806 Hz PC 1.4
FIDRES 0.548877 Hz
AQ 0.9110004 sec
RG 32
DW 55.600 psec
DE 4.50 sec
TE 300.0 K
D1 5 sec
P l. 11.35 Ecsec
SFO1 300.1342018 MHz
WCI 1H
PLl O dB
"C-NMR analysis
F2-Acquisition parameters F2-Processing parameters
27
CA 02619473 2008-02-14
WO 2007/035890 PCT/US2006/036875
Instrument dpx 300
Probhd 5mm Dual Z5 SI 16384
Pulprog zgdc SF 75.4677549MHz
TD 16384 WDW EM
Solvent CDC13 SSB 0
NS 5043 LB 10.00 Hz
DS 0 GB 0
SWH 18832.393 Hz PC 1.4
FIDRES 1.149438 Hz
AQ 0.4350452 sec
RG 5792.6
DW 26.550 sec
DE 4.50 sec
TE 300.0 K
D11 - 0.03 sec
PL12 17.8Db
Cpdprg2 waltz 16
PCPD2 90.00 sec
SF02 300.1330013 MHz
NUC2 1H
PL2 0 dB
DI lsec
Pi 9.4 sec
DE 4.5 sec
SFOI 75.4767751 MHz
NUC1 13C
PLl 0dB
IR analysis
KBr pellets
Number of sample scans 16
Number of background scans 16
Scanning parameters 4000-500 cm-1
28
CA 02619473 2008-02-14
WO 2007/035890 PCT/US2006/036875
Resolution 4
Sample gain 8
Mirror velocity 0.6329
Aperture 100
X-ray analysis
Instrument SIEMENS " Model : D-5000
Copper radiation 1.5406 A
Scanning parameters 2-50 20.
Step scan 0.03
Step time 0.5 second
Example 1: Preparation of (3 S) 5-methyl-3-(2-oxo-2 f [(1 SLphenylethyllamino)
ethyl) hexanoic acid compound (24)
[00128] A three-necked flask equipped with an addition funnel, thermometer
pocket, drying tube and a mechanical stirrer, was charged with toluene (400
ml),
(S)-(-)-phenylethylamine (142.35 g,1.1764 mole), and 4-dimethylaminopyridine
(0.7176 g, 0.0059 mole). The mixture was cooled to a temperature of -10 C to -
15 C,
followed by addition of a solution of.3-isobutyl glutaric anhydride (100 g,
0.59 mole)
in toluene (100 ml), over a period of 45-60 minutes, and stirring for
additional 1.5-2
hours, at a temperature of -10 C to -15 C . The mixture was then extracted
with 10%
aqueous solution of NaOH (500 ml), and the aqueous phase was washed with
toluene
(1x250 ml). The pH of the aqueous phase was adjusted to 2-2.5 by adding a
solution
of hydrochloric acid (1-12N). The aqueous phase was further extracted with
toluene
(lx 800 ml) at a temperature of 70-80 C. The toluene layer was washed with 10%
sodium chloride solution {700m1) at a temperature of 70-80 C followed by
crystallization to get 125 g (73.0% yield) of a white solid of (3S)-5-methyl-3-
(2-oxo-
2-{[(1S)-1-phenylethy1]amino}ethyl) hexanoic acid with an optical purity of
99.75
%, as measured by chiral BPLC.
29
CA 02619473 2008-02-14
WO 2007/035890 PCT/US2006/036875
Example 2: Preparation of (3S)-5-methyl-3-(2-oxo-2 [(1S)-1-phenylethyl]amino}
ethyl) hexanoic acid compound (24)
[00129] A three-necked flask equipped with an addition funnel, thermometer
pocket, drying tube and a mechanical stirrer, was charged with toluene (400
ml),
(S)-(-)-phenylethylamine (38.59 g, 0Ø319 mole), and 4-dimethylaminopyridine
(0.358 g, 0.0029 mole). The mixture was cooled to a temperature of -40 C to -
50 C,
followed by addition of a solution of 3-isobutyl glutaric anhydride (50 g,
0.294 mole)
in toluene (100 ml), over a period of 45-60 minutes, and stirring for
additional 1.5-2
hours, at a temperature of -40 C to -50 C. The mixture was then extracted with
3.5-4.0% aqueous solution of NaOH (1000 ml), and the aqueous phase was washed
with toluene (1x250 ml). The pH of the aqueous phase was adjusted to 2-2.5 by
adding a solution of hydrochloric acid (1-12N). The aqueous phase was further
extracted with ethyl acetate (1x300 ml and 1x100 ml), followed by drying the
combined ethyl acetates extracts over anhydrous sodium sulphate, and stripping
off
the solvents to obtain a residue. The residue was crystallized from ethyl
acetate and
toluene mixture to get 60.7 g (71.0% yield) of a white solid of (3S)-5-methyl-
3-(2-
oxo-2-{[(1S)-1-phenylethyl]amino }ethyl) hexanoic acid with an optical purity
of
99.75 %, as measured by chiral HPLC.
Example 3: Preparation of (3S)-5-methyl-3-(2-oxo-2 {[(1Sphenylethyl]amino}}
ethyl) hexanoic acid compound (24)
[00130] - A three-necked flask equipped with an addition funnel, thermometer
pocket, drying tube and a mechanical stirrer, was charged with toluene (1000
ml),
(S)-(-)-phenylethylamine (266.9 g, 2.206 mole), and 4-dimethylaminopyridine
(1.79
g, 0.0147 mole). The mixture was cooled to a temperature of -40 C to -50 C,
followed by addition of a solution of 3-isobutyl glutaric anhydride (250 g,
1.471
mole) in toluene (250ml), over a period of 45-60 minutes, and stirring for
additional
1.5-2 hours, at a temperature of -40 C to -50 C. The mixture was then
extracted with
3.5-4.0% aqueous solution of NaOH (2350 ml), and the aqueous phase was washed
with toluene (1x250 ml). The pH of the aqueous phase was adjusted to 2-2.5 by
adding a solution of hydrochloric acid (1-12N). The aqueous phase was further
extracted with ethyl acetate (1x1250 ml and 1x500 ml), followed by drying the
CA 02619473 2008-02-14
WO 2007/035890 PCT/US2006/036875
combined ethyl acetates extracts over anhydrous sodium sulphate, and stripping
off
the solvents to obtain a residue. The residue was crystallized from toluene to
get 344
g (80.5% yield) of a white solid of (3S)-5-methyl-3-(2-oxo-2-{[(lS)-l-
phenylethyl] amino} ethyl) hexanoic acid with an optical purity of 98.69 %, as
measured by chiral HPLC.
Example 4: Preparation of (R)-3-isobutylpentanedioic acid amide-(
phenylethy)amide (25)
[00131] A three-necked flask equipped with an addition funnel, thermometer
pocket, drying tube and a mechanical stirrer, was charged with methylene
dichloride
(1000 ml), (3S)-5-methyl-3-(2-oxo-2{ [(1 S)-1-phenylethyl] amino} ethyl)
hexanoic
acid compound (24) (200 g, 0.687 mole), and with triethylamine (7.65g, 0.756
mole),
and cooled to 0 -5 C followed by addition of ethyl chloroformate (90 g, 0.825
mole).
The mixture was stirred for 1-2 hours at a temperature'of 20 C to 25 C,
followed by
quenching with 25% aqueous ammonia (1000 ml). The resulted slurry was filtered
and washed with water and dried to get 140 g (70.0% yield) of a white solid of
(R)-3-isobutylpentanedioic acid amide-((S)- 1 -phenylethyl)amide of formula
25A,
with a purity of 95%, as measured by HPLC.
Example 5: Preparation of (R)-3-isobutylpentanedioic acid amide-((S)-1-
phenyllethyl)amide (25)
[00132] A three-necked flask equipped with an addition funnel, thermometer
pocket, drying tube and a mechanical stirrer, was charged with methylene
dichloride
(500 ml), (3S)-5-methyl-3-(2-oxo-2{[(1 S)-1-phenylethyl] amino }
ethyl)hexanoic acid
compound (24) (100 g, 0.343 mole), and with triethylamine (41.67g, 0.412mole),
and
cooled to -15 C to -20 C followed by addition of ethyl chloroformate (39.1 g,
0.36
mole). The mixture was stirred for 1-2 hours at a temperature of -15 C to -20
C,
followed by quenching over a solution of 20% aqueous ammonia (280m1). The
dichloromethane was distilled out from the mass followed by filtering the
resulted
slurry, washed with water and dried to get 87 g (87% yield) of a white solid
of
(R)-3-isobutylpentanedioic acid amide-((S)-1-phenylethyl)amide of formula 25A,
with a purity of 98%, as measured by HPLC.
31
CA 02619473 2008-02-14
WO 2007/035890 PCT/US2006/036875
Example 6: Preparation of (R)-3-isobutylpentanedioic acid amide-((S)-1-
phenyleth .mil)
amide 25
[00133] A three-necked flask equipped with an addition funnel, thermometer
pocket, drying tube and a mechanical stirrer, was charged with methylene
dichloride
(125 ml), (3S)-5-methyl-3-(2-oxo-2{[(1S)-1-phenylethyl]amino} ethyl) hexanoic
acid compound (24) (25 g, 0.086 mole), triethyl amine (10.43 g, 0.129 mole),
and
cooled to 0 -5 C followed by addition of pivaloyl chloride (12.43 g, 0.103
mole).
The mixture was stirred for 1-2 hours at a temperature of 20 C to 25 C,
followed by
quenching with 20% aqueous ammonia (250 ml). The resulted slurry was filtered
and
washed with water and dried to get 15.2 g (61 % yield) of a white solid of
(R)-3-isobutylpentanedioic acid amide-((S)-1-phenylethyl)amide of formula 25A,
with a purity of 95%, as measured by HPLC.
Example 7: Preparation of (R -3-isobutylpentanedioic acid amide-((S)-
l:phenylethyl)
amide 25
[00134] A three-necked flask equipped with an addition funnel, thermometer
pocket, drying tube and a mechanical stirrer, was charged with acetone (125
ml),
(3S)-5-methyl-3-(2-oxo-2{ [(1 S)-1-phenylethyl] amino } ethyl) hexanoic acid
compound (24) (25 g, 0.086 mole), triethyl amine (10.43 g, 0.129 mole), and
cooled
to 0-5 C followed by addition of pivaloyl chloride (12.43 g, 0.103 mole). The
mixture was stirred for 1-2 hours at a temperature of 20 C to 25 C, followed
by
quenching with 20% aqueous ammonia ( 250 ml). The resulted slurry was filtered
and washed with water and dried to get 10.68 g (43.4% yield) of a white solid
of
(R)-3-isobutylpentanedioic acid amide-((S)-1-phenylethyl)amide of formula 25,
with
a purity of 95.4%, as measured by HPLC.
Example 8: Preparation of (S)-4-methyl-2-[((S)-1-phenylethylcarbamoyl)-
I carbamic acid methyl ester (26)
methyllpentyl
[00135] A three-necked flask equipped with an addition funnel, thermometer
pocket, drying tube and a mechanical stirrer, was charged with methanol (1400
ml),
and cooled to -40 to -45 C followed by addition of sodium methoxide (130 g,
2.413
mole). A solution of bromine (154.48 g, 0.965 mole) in methanol (300 ml) was
slowly added at about -40 to -45 C followed by addition of
32
CA 02619473 2008-02-14
WO 2007/035890 PCT/US2006/036875
(R)-3-isobutylpentanedioic acid amide-((S)-1-phenylethyl)amide, of formula
25(140
g, 0.48 mole), in methanol (560 ml). The mixture was gradually warmed to a
temperature of 0 C and then to 55-60 C, followed by stirring for 2 to 3 hours.
The
solvent was then stripped off and water was added to the mass. The resulted
slurry
was further extracted with methylene dichloride (1x500 ml and 1x250 ml),
followed
by drying the combined methylene dichloride extracts over anhydrous sodium
sulphate, and stripping off the solvents to obtain a residue. The residue was
crystallized from diisopropyl ether to get 115 g (74.2.0% yield) of a white
solid of
{(S)-4-methyl-2-[((S)-1-phenylethylcarbamoyl)-methyl]pentyl}carbamic acid
methyl
ester (26) with a purity of 92%, as measured by HPLC.
Example 9: Preparation of f(S)-4-methyl-2-1((S)-l::phenylethylcarbamoyl)-
methyl]pentyl}carbamic acid methyl ester (26)
[00136] A three-necked flask equipped with an addition funnel, thermometer
pocket, drying tube and a mechanical stirrer, was charged with methanol (2000
ml),
and cooled to -15 to -20 C, (R)-3-isobutylpentanedioic acid amide-((S)-1-
phenylethyl)amide, of formula 25(100 g, 0.344 mole) followed by addition of
sodium
methoxide (74.5 g, 1.38 mole). Bromine (82.56 g, 0.516 mole) was slowly added
at
about -15 to -20 C. The mixture was gradually warmed to a temperature of 0 C
and
then to 55-60 C, followed by stirring for 2 to 3 hours. The solvent was then
stripped
off,and water was added to the mass. The resulted slurry was further extracted
with
methylene dichloride (1x500 ml), followed by washing the methylene dichloride
extract with water and brine solution. The solvent was stripped off and the
residue
was crystallized from a mixture of methylene dichloride and cyclohexane to get
95g
(85.8.0% yield) of a white solid of {(S)-4-methyl-2-[((S)-1-
phenylethylcarbamoyl)-
methyl]pentyl}carbamic acid methyl ester (26) with a purity of 93%, as
measured by
HPLC.
Example 10: Preparation of {(S)-2-carbamo l~yl-4-methylpent l)carbamic acid
methyl ester (27)
[00137] A 2 1, four-necked flask, equipped with a mechanical stirrer,
thermometer pocket and a liquid ammonia inlet, was charged with {(S)-4-methyl-
2-
[((S)-1-phenylethylcarbamoyl)-methyl]pentyl}carbamic acid methyl ester (26)
(25 g,
33
CA 02619473 2008-02-14
WO 2007/035890 PCT/US2006/036875
0.078 mole), tetrahydrofuran (175 ml), and water (25 ml). The reaction mixture
was
cooled to -40 to -60 C and liquid ammonia (1000 ml) was added followed by
addition of small pieces of sodium metal (7.2 g). The resultant reaction
mixture was
stirred vigorously for 4-10 hours until the ammonia had evaporated. Water (100
ml)
was added to the reaction mass under N2 atmosphere at 5 -10 C, followed by
separating the phases. The organic layer was separated and dried over
anhydrous
sodium sulphate and the solvent was stripped off. The residue was crystallized
from
diisopropyl ether to get 10.2 g (60% yield) of {(S)-2-carbamoylmethyl-4-
methylpentyl)carbamic acid methyl ester with purity of 73% as measured by
HPLC.
Example 11: Regeneration of 3-isobutylglutaric acid
[00138] A 3 1 four-necked flask, equipped with a mechanical stirrer,
thermometer pocket, and condenser, was charged with a residue after
crystallization
of compound 24A,(250 g) from examples 1 and 2, and 70% sulfuric acid (2500 g).
The reaction mixture was refluxed at 115 -125 C for 5-10 hours, and then
cooled to
20 -25 C and diluted with water. The aqueous layer was extracted with toluene
(lx1000 ml and 1x500 ml). The combined organic phase was extracted with 5%
sodium hydroxide solution (1500 ml), and the pH of the aqueous layer was
adjusted to
1.5-2 with concentrated hydrochloric acid, followed by extractions with
toluene
(1x600 ml and 1x400 ml). The combined organic layers were dried over anhydrous
sodium sulphate and the solvent was stripped off to obtain 3-isobutyl glutaric
acid
(128 g) in purity of 94% as measured by GC.
[00139] 3-isobutylglutaric acid is characterized by:
1. IR (KBr) : 1713.27 cm-1.
2. 1H NMR (CDC13): 5 0.89-0.92 (d, 6H), 1.25 (t, 2H), 1.6-1.69 (septet, 1H),
2.42 (s,
4H), 11.96 (s,2H).
3. 13C NMR (CDC13): 8 22.39, 25.06, 28.11, 29.50, 38.45, 43.38, 179.17, 203.
Example 12: Converting3-isobutylglutaric acid to 3-isobutylglutaric anhydride,
compound 22
[00140] A 11, four-necked flask equipped with a mechanical stirrer,
thermometer pocket and condenser, was charged with 3-isobutyl glutaric acid
(500 g)
and acetic anhydride (326 g). The reaction mixture was refluxed at 135 -1450 C
for
34
CA 02619473 2008-02-14
WO 2007/035890 PCT/US2006/036875
2.5-3 hours, followed by distilling out the unreacted acetic anhydride at 147 -
155 C,
and then the distillation was continued under vacuum to ensure removal of
traces of
unreacted acetic anhydride. The residue was cooled to 25 -30 C to obtain 445 g
of
3-isobutylglutaric anhydride.
Example 13: Preparation of (S -Pre abalin
[00141] A 0.2 1 reactor was loaded with 6N hydrochloric acid (100 ml)
containing compound 27 (12 g, 0.055 mole), and was heated to 100 -110 C for 12-
24
hours, and then cooled to room temperature, i.e., about 20 to about 25 C. An
aqueous 40% sodium hydroxide solution was added in an amount sufficient to
provide
a pH of 1. The solution was then extracted with 37 ml of iso-butanol, the
organic
layer was separated, and Bu3N was added in an amount sufficient to provide a
pH of
4. The (S)-Pregabalin was precipitated, filtered, and washed with 10 ml of iso-
butanol. After drying at 55 C under vacuum, (S)-Pregabalin was obtained as
white
crystals in a 21.5% yield. Purity: 99.9% area by HPLC.
Example 14: Preparation of (S -Pre ag balin
[00142] A 0.2 1 reactor was loaded with 70% sulfuric acid (200 g) containing
compound 26 (10 g, 0.031 mole), and was heated to 115-120 C for 5-10 hours,
and
then cooled to room temperature, i.e., about 20 to about 25 C. An aqueous 40%
sodium hydroxide solution was added in an amount sufficient to provide a pH of
1.
The solution was then extracted with 35 ml of iso-butanol, the organic layer
was
separated, and Bu3N was added in an amount sufficient to provide a pH of 4.
The
(S)-Pregabalin was precipitated, filtered, and washed with 10 ml of iso-
butanol. After
drying at 55 C under vacuum, (S)-Pregabalin was obtained as white crystals in
a
40.4% yield. Purity: 99.95% area by HPLC.
Example 15: Preparation of (S)-Pre ag balin
[00143] A 0.2 1 reactor was loaded with 70% sulfuric acid (200 g) containing
compound 26 (10 g, 0.031 mole), and was heated to 115-120 C for 5-10 hours,
and
then cooled to room temperature, i.e., about 20 to about 25 C. An aqueous 40%
sodium hydroxide solution was added in an amount sufficient to provide a pH of
1.
The solution was then extracted with 50 ml of isopropanol, the organic layer
was
CA 02619473 2008-02-14
WO 2007/035890 PCT/US2006/036875
separated, and NH4OH was added in an amount sufficient to provide a pH of 4.
The
(S)-Pregabalin was precipitated, filtered, and washed with 10 ml of
isobutanol. After
drying at 55 C under vacuum, (S)-Pregabalin was obtained as white crystals in
a
50.4% yield. Purity: 99.05% area by HPLC.
Example 16: Preparation of (S)-Pre ag balin
[00144] A flask was loaded with 47% HBr (12 ml), water (6 ml), and
compound 26 (6 g), and then was heated to reflux for 3 hours. The solution was
cooled to room temperature, and water (12 ml) was added. An aqueous 47% sodium
hydroxide solution was added to obtain pH of 3. The solution was then
extracted
twice with isobutanol (15 ml), the combined organic layers were evaporated and
fresh
isobutanol was added (15 ml). Bu3N (3.8 g) was added. The mixture was cooled
to
2 C for 1 hour, then (S)-Pregabalin was filtered, and washed with of iso-
butanol
(3 ml). After drying at 55 C under vacuum, (S)-Pregabalin was obtained as
white
crystals in a 90% yield.
Example 17: Preparation of (S)-Pre abalin
[00145] A flask was loaded with 47% HBr (30 ml), water (15 ml), and
compound 26 (15 g), and then was heated to reflux for 3 hours. The solution
was
cooled to room temperature and water (30 ml) was added. An aqueous 47% sodium
hydroxide solution was added to obtain pH of 3. The solution was then
extracted
twice with iso-butanol (37.5 ml). The organic layers were combined and Bu3N
(9.5 g)
was added. The mixture was cooled to 2 C for 1 hour, then (S)-Pregabalin was
filtered, and washed with of iso-butanol (10 ml). After drying at 55 C under
vacuum,
(S)-Pregabalin was obtained as white crystals in a 51% yield.
[00146] While it is apparent that the invention disclosed herein is well
calculated to fulfill the objects stated above, it will be appreciated that
numerous
modifications and embodiments may be devised by those skilled in the art.
Therefore,
it is intended that the appended claims cover all such modifications and
embodiments
as falling within the true spirit and scope of the present invention.
36
